Mycobacterial coxitis masked by concomitant staphylococcal infection after infliximab for Crohn's disease.
Dhawan
Saurabh S
SS
Finks
A Lloyd
AL
Wang
Benjamin W E
BW
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification* / Q000502:physiology; D009161:Mycobacterium / Q000302:isolation & purification* / Q000502:physiology; D010019:Osteomyelitis / Q000382:microbiology* / Q000473:pathology; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome; D014394:Tuberculosis, Osteoarticular / Q000150:complications* / Q000188:drug therapy / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000995:Antitubercular Agents; D000069285:Infliximab